![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release